Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPELLA: Lenacapavir in Heavily Treatment-Experienced People With Multidrug-Resistant HIV-1
jRCT2080225169Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of lenacapavir in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Started Apr 2020; status: completed.
02
Drugs
lenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2080225169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225169.